canova south africa 17 november 2005 presented by: dr m mojapelo

16
CANOVA South Africa CANOVA South Africa 17 November 2005 17 November 2005 Presented By: Dr M Mojapelo

Upload: lucy-dean

Post on 18-Dec-2015

216 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

CANOVA South AfricaCANOVA South Africa

17 November 200517 November 2005

Presented By: Dr M Mojapelo

Page 2: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Dr Maggie MojapeloDr Maggie Mojapelo Medical doctorMedical doctor Founder of Clinics of HopeFounder of Clinics of Hope

Has been involved in Has been involved in HIV/AIDS integrated HIV/AIDS integrated management/wellness for management/wellness for the the past 15 yearspast 15 years

Conducted a prospective study on Canova in SA

Page 3: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

INTRODUCTIONINTRODUCTION

““Canova is a powerful immune Canova is a powerful immune modulator and a modulator and a

complementary medicine complementary medicine which does not present which does not present

toxicity or known side effects toxicity or known side effects to patients ”to patients ”

Page 4: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo
Page 5: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Resting macrophage

Phagocytosis

CD4

CD8 and NK

B cell

CD4

MacrophageActivated macrophage

Antigen presenting

IMMUNE SYSTEM - CELL INTERACTIONSIMMUNE SYSTEM - CELL INTERACTIONS

Page 6: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Resting macrophage

Phagocytosis

Antigen presenting

How Canova Works?How Canova Works? How Canova Works?How Canova Works?

?

CANOVAActivated macrophage

Molecules are produced to all the immune system

TNF, Nitric Oxid

Page 7: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Clinical Study Clinical Study Conducted at Johannesburg from April 2005 to Conducted at Johannesburg from April 2005 to

datedate 30 HIV positive patients30 HIV positive patients Selection criteriaSelection criteria Clinical Parameters Measured:Clinical Parameters Measured:

– AppetiteAppetite– Weight lossWeight loss– Opportunistic infectionsOpportunistic infections– Energy levelsEnergy levels

Laboratory Parameters Measured:Laboratory Parameters Measured:– Viral Load Viral Load – CD4 count CD4 count

Page 8: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Findings of the Clinical Findings of the Clinical StudyStudy

All 30 patients tolerated CanovaAll 30 patients tolerated Canova

– Viral LoadViral Load 90 % Decrease 90 % Decrease– CD4 CountCD4 Count 70 % Increase 70 % Increase– Weight Weight 93 % Increase 93 % Increase– AppetiteAppetite 80 % Increase 80 % Increase– Opportunistic infections Opportunistic infections 80 % Decrease80 % Decrease

Page 9: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Viral LoadViral Load

Findings of the Clinical StudyFindings of the Clinical Study

Viral Load

0

2000

4000

6000

8000

10000

12000

Month 1 Month 2 Month 3 Month 4

Viral Load

Page 10: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Findings of the Clinical StudyFindings of the Clinical Study

CD4 CountCD4 CountCD4 Count

0

100

200

300

400

500

600

700

Month 1 Month 2 Month 3 Month 4

CD4 Count

Page 11: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Findings of the Clinical StudyFindings of the Clinical Study

WeightWeightWeight

0

20

40

60

80

100

120

Month 1 Month 2 Month 3 Month 4

Weight

Page 12: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Findings of the Clinical StudyFindings of the Clinical StudyAppetiteAppetite

Appetite

0

5

10

15

20

25

Month 1 Month 2 Month 3 Month 4

Appetite

Page 13: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Findings of the Clinical ResearchFindings of the Clinical ResearchOpportunistic infections

Atypical Pneumonia - Skin Rashes - Neuropathies -Oral Thrush -Atypical Pneumonia - Skin Rashes - Neuropathies -Oral Thrush -ShinglesShingles

After 3 months of treatment 80% of the OI’s showed marked improvement

Page 14: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Canova BenefitsCanova Benefits Canova is a type of medication that helps Canova is a type of medication that helps

resuscitate a depressed immune system. resuscitate a depressed immune system. Canova helps boost the immune system.Canova helps boost the immune system. Helps to fight all kinds of compromised immune Helps to fight all kinds of compromised immune

systems related problems. systems related problems. Canova's effect of activating and enlarging the Canova's effect of activating and enlarging the

macrophages helps to decrease the incidence macrophages helps to decrease the incidence of opportunistic infections. of opportunistic infections.

Canova has no known side effects. Canova has no known side effects. Considerable improvement on the quality of Considerable improvement on the quality of

life.life.

Page 15: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

Canova ProductCanova ProductCanova is available in two forms: Canova is available in two forms:

CANOVA DROPS

CANOVA INHALATION

Page 16: CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo

ConclusionConclusion Clinically Canova has shown Clinically Canova has shown massive massive

impact on quality of lifeimpact on quality of life The importance of Canova is the The importance of Canova is the

absence of known side effectsabsence of known side effects Canova can be used as a Canova can be used as a monotherapy monotherapy

or in combination with ARV’sor in combination with ARV’s Results show that Canova has a Results show that Canova has a positive positive

effect on Opportunistic infectionseffect on Opportunistic infections